Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9

Schulz, Heiko; Kühn, Christina; Hofmann, Simone; Mayr, Doris; Mahner, Sven; Jeschke, Udo; Schmoeckel, Elisa

doi:10.3390/ijms19010323

Cited by 25 publications

(42 citation statements)

References 39 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exclusion criteria were neoadjuvant chemotherapy as well as benign or borderline tumors. Previously, other pathological parameters were investigated in the same patients' collective, which enables correlation analysis [14][15][16][17]. Clinical data derived from patients' charts, follow up data from Munich Cancer Registry.…”

Section: Patients and Specimensmentioning

confidence: 99%

“…For immunohistochemistry staining, a protocol previously described by our lab was used [17]. Tissue micro arrays of FFPE EOC samples were deparaffinized for 20 min in roticlear (Roth, Kalsruhe, Germany), incubated for 20 min in methanol containing 3% H 2 O 2 to quench the endogen peroxidase, rehydrated in a descending series of alcohol (100-50%), and cooked for 5 min in a pressure cooker containing a sodium-citrate buffer (0.1 M citric acid, 0.1 M sodium citrate, pH = 6.0).…”

Section: Immunohistochemistrymentioning

confidence: 99%

See 1 more Smart Citation

M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis

Badmann

Heublein

Mayr

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

Multi drug resistance protein 1 (MDR1) expression on tumor cells has been widely investigated in context of drug resistance. However, the role of MDR1 on the immune cell infiltrate of solid tumors remains unknown. The aim of this study was to analyze the prognostic significance of a MDR1+ immune cell infiltrate in epithelial ovarian cancer (EOC) and to identify the MDR1+ leucocyte subpopulation. MDR1 expression was analyzed by immunohistochemistry in 156 EOC samples. In addition to MDR1+ cancer cells, we detected a MDR1+ leucocyte infiltrate (high infiltrate >4 leucocytes per field of view). Correlations and survival analyses were calculated. To identify immune cell subpopulations immunofluorescence double staining was performed. The MDR1+ leucocyte infiltrate was associated with human epidermal growth factor receptor 2 (HER2) (cc = 0.258, p = 0.005) and tumor-associated mucin 1 (TA-MUC1) (cc = 0.202, p = 0.022) expression on cancer cells. A high MDR1+ leucocyte infiltrate was associated with impaired survival, especially in patients whose carcinoma showed either serous histology (median OS 28.80 vs. 50.64 months, p = 0.027, n = 91) or TA-MUC1 expression (median OS 30.60 vs. 63.36 months, p = 0.015, n = 110). Similar findings for PFS suggest an influence of MDR1+ immune cells on the development of chemoresistance. A Cox regression analysis confirmed the independency of a high MDR1+ leucocyte infiltrate as prognostic factor. M2 macrophages were identified as main part of the MDR1+ leucocyte infiltrate expressing MDR1 as well as the M2 marker CD163 and the pan-macrophage marker CD68. Infiltration of MDR1+ leucocytes, mostly M2 macrophages, is associated with poor prognosis of EOC patients. Further understanding of the interaction of M2 macrophages, MDR1 and TA-MUC1 appears to be a key aspect to overcome chemoresistance in ovarian cancer.

show abstract

Section: Patients and Specimensmentioning

confidence: 99%

Section: Immunohistochemistrymentioning

confidence: 99%

M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis

Badmann

Heublein

Mayr

et al. 2020

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, 8 of 12 ovarian cancer tissues had what was deemed medium Gal-8 expression. Based on these preliminary findings, Schulz and colleagues [ 93 ] chose to evaluate 156 ovarian cancer samples using immunohistochemistry and compared the Gal-8 levels and its localization with clinical and pathological outcomes. Of the 156 ovarian cancer samples, they were able to evaluate 143 samples for Gal-8.…”

Section: Galectin-8 (Lgals8)mentioning

confidence: 99%

Galectins and Ovarian Cancer

Shimada

Rui

Al-Alem

et al. 2020

Cancers

View full text Add to dashboard Cite

Ovarian cancer is known for its aggressive pathological features, including the capacity to undergo epithelial to mesenchymal transition, promoting angiogenesis, metastatic potential, chemoresistance, inhibiting apoptosis, immunosuppression and promoting stem-like features. Galectins, a family of glycan-binding proteins defined by a conserved carbohydrate recognition domain, can modulate many of these processes, enabling them to contribute to the pathology of ovarian cancer. Our goal herein was to review specific galectin members identified in the context of ovarian cancer, with emphasis on their association with clinical and pathological features, implied functions, diagnostic or prognostic potential and strategies being developed to disrupt their negative actions.

show abstract

“…The cluster worded “Galectins and Cancer”, as expected, is the larger one. The cluster includes several papers focused on cancer diagnosis, prognosis, and galectin-based therapeutic approaches [ 4 , 5 , 6 , 7 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ]. The implication of galectins in tumor growth and progression, and more in general the impact that these molecules may have in oncology, is very well-known and has been extensively reviewed [ 3 ].…”

mentioning

confidence: 99%

“…Modulation of these galectin-1 related molecules may have prognostic value for this tumor type. Similarly, a specific galectin signature, which can be used as prognostic marker, has been also identified in ovarian carcinoma [ 14 , 15 ].…”

mentioning

confidence: 99%